Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan; Japan Science and Technology Agency (JST) Fusion Oriented REsearch for disruptive Science and Technology (FOREST) Program, Japan.
Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan.
J Control Release. 2022 Aug;348:357-369. doi: 10.1016/j.jconrel.2022.05.033. Epub 2022 Jun 9.
The recent rapid progress in the area of drug delivery systems (DDS) has opened a new era in medicine with a strong linkage to understanding the molecular mechanisms associated with cancer survival. In this review, we summarize new cancer strategies that have recently been developed based on our DDS technology. Cancer immunotherapy will be improved based on the concept of the cancer immunity cycle, which focuses on dynamic interactions between various types of cancer and immune cells in our body. The new technology of genome editing will also be discussed with reference to how these new DDS technologies can be used to introduce therapeutic cargoes into our body. Lastly, a new organelle, mitochondria will be the focus of creating a new cancer treatment strategy by a MITO-Porter which can deliver macromolecules directly to mitochondria of cancer cells via a membrane fusion approach and the impact of controlled intracellular trafficking will be discussed.
近年来,药物输送系统(DDS)领域的快速发展为医学开辟了一个新纪元,与理解与癌症生存相关的分子机制紧密相连。在这篇综述中,我们总结了最近基于我们的 DDS 技术开发的新癌症策略。癌症免疫疗法将基于癌症免疫循环的概念得到改善,该概念侧重于我们体内各种类型的癌症和免疫细胞之间的动态相互作用。我们还将参考基因组编辑的新技术,讨论这些新的 DDS 技术如何用于将治疗性货物递送到我们体内。最后,一个新的细胞器线粒体将成为焦点,通过膜融合方法,MITO-Porter 可以将大分子直接递送到癌细胞的线粒体中,从而创建一种新的癌症治疗策略,并讨论受控细胞内运输的影响。